{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:15Z","timestamp":1787168715542,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"am","delay-in-days":674,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114499","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:46:23Z","timestamp":1653817583000},"page":"114499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective \u03b2-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease"],"prefix":"10.1016","volume":"238","author":[{"given":"Jun-Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Shimadate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Mei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.J.","family":"Fleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-0349","authenticated-orcid":false,"given":"Chu-Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114499_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114499_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10409239009090616","article-title":"Acid \u03b2-glucosidase: enzymology and molecular biology of Gaucher diseas","volume":"25","author":"Grabowski","year":"1990","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114499_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1039\/B915870G","article-title":"Glycosidase inhibition: assessing mimicry of the transition state","volume":"8","author":"Gloster","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fnagi.2020.00097","article-title":"Glucocerebrosidase defects as a major risk factor for Parkinson's disease","volume":"12","author":"Avenali","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2022.114499_bib5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.26802","article-title":"Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease","volume":"31","author":"Wong","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2022.114499_bib6","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/ijms20133304","article-title":"The link between Gaucher disease and Parkinson\u2019s disease sheds light on old and novel disorders of sphingolipid metabolism","volume":"20","author":"Indellicato","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114499_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14712590802573395","article-title":"Enzyme replacement therapy for Gaucher disease","volume":"9","author":"Charrow","year":"2009","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2022.114499_bib8","article-title":"Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy","volume":"20","author":"Beshlawy","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ejmech.2022.114499_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114499_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1568026033452483","article-title":"Therapeutic applications of imino sugars in lysosomal storage disorders","volume":"3","author":"Butters","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14756366.2020.1791841","article-title":"Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor","volume":"35","author":"Li","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/14656566.8.4.427","article-title":"Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders","volume":"8","author":"Butters","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114499_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114499_bib14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2022.114499_bib15","doi-asserted-by":"crossref","first-page":"PMC.S2332","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14656566.2021.1902989","article-title":"Current and emerging pharmacotherapy for Gaucher disease in pediatric populations","volume":"22","author":"Sam","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114499_bib17","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of \u03b2-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2022.114499_bib18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/cbic.200600217","article-title":"Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease","volume":"7","author":"Compain","year":"2006","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2022.114499_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2022.114499_bib20","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1021\/acs.chemrev.8b00532","article-title":"Folding and misfolding of human membrane proteins in health and disease: from single molecules to cellular proteostasis","volume":"119","author":"Marinko","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2022.114499_bib21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse Protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2022.114499_bib22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114499_bib23","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1021\/ja034917k","article-title":"Direct observation of the protonation state of an imino sugar glycosidase inhibitor upon binding","volume":"125","author":"Varrot","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114499_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2020.107988","article-title":"A common strategy towards the synthesis of 1,4-dideoxy-1,4-imino-l-xylitol, deacetyl (+)-anisomycin and amino-substituted piperidine iminosugars","volume":"492","author":"Harit","year":"2020","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2022.114499_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cmdc.201700706","article-title":"Synthesis of N-substituted iminosugar derivatives and evaluation of their immunosuppressive activities","volume":"13","author":"Lv","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114499_bib26","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm201633y","article-title":"Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease","volume":"55","author":"Goddard-Borger","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib27","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1021\/jo200176u","article-title":"Synthesis and fucosidase inhibitory study of unnatural pyrrolidine alkaloid 4-epi-(+)-codonopsinine","volume":"76","author":"Kotland","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib28","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.1002\/ange.200502662","article-title":"Rational design and synthesis of highly potent \u03b2-glucocerebrosidase inhibitors","volume":"117","author":"Zhu","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2022.114499_bib29","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid \u03b2-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2022.114499_bib31","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1002\/ejoc.202000522","article-title":"Synthesis of isofagomine derivatives as new fluorescence pH indicators\/glycosidase inhibitors","author":"Wang","year":"2020","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tetasy.2004.11.067","article-title":"The l-enantiomers of d-sugar-mimicking iminosugars are noncompetitive inhibitors of d-glycohydrolase?","volume":"16","author":"Asano","year":"2005","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1016\/j.ejmech.2022.114499_bib33","doi-asserted-by":"crossref","first-page":"14313","DOI":"10.1021\/ja036833h","article-title":"Iminosugar glycosidase inhibitors: structural and thermodynamic dissection of the binding of isofagomine and 1-deoxynojirimycin to \u03b2-glucosidases","volume":"125","author":"Zechel","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114499_bib34","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/ja973443k","article-title":"1-N-Iminosugars: potent and selective inhibitors of \u03b2-glycosidases","volume":"120","author":"Ichikawa","year":"1998","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114499_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4155\/fmc.13.14","article-title":"Glucocerebrosidase inhibitors for the treatment of Gaucher disease","volume":"5","author":"Trapero","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7164\/antibiotics.49.155","article-title":"Inhibition of mouse tumor metastasis with nojirimycin-related compounds","volume":"49","author":"Tsuruoka","year":"1996","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2022.114499_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid \u03b2-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejmech.2022.114499_bib38","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2022.114499_bib39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114499_bib40","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"\u03b1-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib41","series-title":"A Class of Polyhydroxylated Pyrrolidines, Preparation and Their Applications","author":"Yu","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114499_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1039\/C5OB02223A","article-title":"Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease","volume":"14","author":"Kato","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib43","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3390\/molecules23102683","article-title":"Design of a new alpha-1-C-Alkyl-DAB derivative acting as a pharmacological chaperone for beta-glucocerebrosidase using ligand docking and molecular dynamics simulation","volume":"23","author":"Nakagome","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114499_bib44","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/chem.200304718","article-title":"Highly diastereoselective additions to polyhydroxylated pyrrolidine cyclic imines: ready elaboration of aza-sugar scaffolds to create diverse carbohydrate-processing enzyme probes","volume":"9","author":"Chapman","year":"2003","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2022.114499_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114230","article-title":"Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives","volume":"233","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib46","first-page":"1407","article-title":"Prediction of n-octanol\/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices","volume":"41","author":"Tetko","year":"2001","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2022.114499_bib47","article-title":"Diastereoselective synthesis, glycosidase inhibition, and docking study of C-7-Fluorinated casuarine and Australine derivatives","author":"Li","year":"2022","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114499_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0005-2736(78)90440-6","article-title":"A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes","volume":"506","author":"Kessler","year":"1978","journal-title":"Biochim. Biophys. Acta"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:13:47Z","timestamp":1728382427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"alternative-id":["S0223523422004019"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114499","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective \u03b2-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114499"}}